Emphysema Market Size, Share, Epidemiology, Trend Analysis, Therapeutic Pipeline Outlook and Outlook 2032 | Key companies – United Therapeutics, Mereo BioPharma, GlaxoSmithKline and others
DelveInsight’s “Emphysema Market Insights, Epidemiology, and Market Forecast 2032” report provides an in-depth understanding of the disease, historical and forecast epidemiology, and 7MM emphysema market size and share (i.e. USA, EU5 (Germany, Spain, Italy, France and UK) and Japan).
The Emphysema Market Report covers emerging drugs, current treatment practices, individual therapies market share, and current and forecasted market size from 2019 to 2032. It also assesses current treatment practice/algorithm, drivers and barriers in the market and unmet medical needs. opportunities and assess the underlying potential of the market.
Emphysema: an overview
EMphysema is one of the diseases that make up COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it difficult to breathe and get worse over time. According to the American Lung Association, emphysema develops over time and involves the progressive damage to lung tissue, particularly the destruction of the alveoli (small air sacs).
There is no cure for emphysema, however, many treatments are available to help manage the symptoms. Bronchodilator drugs relax muscles, anti-inflammatory drugs can reduce airway inflammation, and oxygen therapy can help patients who need help breathing. In extreme situations, lung volume reduction surgery can relieve pressure by removing some of the diseased lung tissue.
Emphysema Market Key Facts
- The prevalence of emphysema in the United States is approximately 14 million, of which 14% are white male smokers and 3% white male non-smokers. The prevalence is slightly lower for white smokers and African Americans (Pahal et al., 2020).
- According to Pahal et al. (2020), smokers are more likely to have emphysema than non-smokers.
- A rare autosomal recessive inherited disorder, alpha one antitrypsin deficiency, can also cause emphysema and liver abnormalities. However, it only contributes to 1% to 2% of COPD cases.
- According to the Centers for Disease Control and Prevention, the number of adults ever diagnosed with emphysema in the United States was about 3.8 million in 2016.
Emphysema market
The size of the emphysema market is expected to grow over the forecast period owing to the increase in cases in 7MM and the launch of emerging therapies. Better diagnostic services and better understanding of the disease are also expected to drive the growth of the therapeutics market in the coming years.
The market outlook section of the report helps in building a detailed understanding of the historical, current and forecasted. Emphysema market size by analyzing the impact of current and emerging therapies on the market. It also provides an in-depth assessment of market drivers and barriers, unmet needs, and emerging technologies.
The report gives full details of Emphysema Market Trend for each marketed drug and therapies in late-stage development by assessing their impact based on annual therapy cost, inclusion and exclusion criteria, mechanism of action (MoA), competition with others therapies, brand value, their impact on the market and the vision of key opinion leaders.
Emphysema epidemiology
The epidemiology section provides an overview of the historical and current situation Group of patients with emphysema and predicted trends for all seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and projected trends by exploring numerous studies and views from key opinion leaders. The epidemiology section also provides the group of diagnosed patients, future trends and assumptions made.
Segmentation of emphysema epidemiology
- Total number of emphysema prevalent cases
- Total number of diagnosed and treatable cases of emphysema
- Etiology-specific cases of emphysema
- Age-specific cases of emphysema
Emphysema Drug Adoption and Pipeline Development Activities
The drug absorption section focuses on the absorption rate of potential drugs recently launched in the Emphysema market or should be launched during the study period. The analysis covers emphysema market adoption by drugs, patient adoption of therapies, and sales of each drug.
In addition, the therapeutic evaluation section helps to understand which drugs are absorbed the fastest and the reasons for the maximum use of drugs. Moreover, it compares drugs based on their market share.
The report also covers the Emphysema pipeline development activities. It provides valuable information on different therapeutic candidates at various stages and on the main companies involved in the development of targeted therapies. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details and other information on emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/emphysema-market
Therapeutic analysis of emphysema
Around the world, some of the key players are diligently involved in the development of therapies for emphysema. Some of the therapies are at an advanced stage and should be launched in the coming years.
Some of the Key Companies in the Emphysema Market Include:
- Mereo BioPharma
- GlaxoSmithKline
- United Therapeutics
And many more.
Emphysema therapies covered in the report include:
- Alvelestat
- Tyvaso Treprostinil
- Belimumab
And much more.
Get more in-depth insights into emerging therapies and key companies – Emphysema therapies and companies
Table of Contents (TOC)
1. Key information
2. Executive Summary
3. Emphysema Competitive Intelligence Analysis
4. Emphysema Market Overview at a Glance
5. Background and Overview of Emphysema Disease
6. Emphysema patient journey
7. Emphysema epidemiology and patient population
8. Emphysema treatment algorithm, current treatment and medical practices
9. Unmet needs of emphysema
10. Key Parameters of Emphysema Treatment
11. Products marketed for emphysema
12. Emerging Emphysema Treatments
13. Seven Emphysema Major Market Analysis
14. Attribute analysis
15. Emphysema Market Outlook (7 Major Markets)
16. Emphysema Access and Reimbursement Overview
17. KOL views on the emphysema market.
18. Emphysema Market Drivers
19. Emphysema Market Barriers
20. Appendix
21. DelveInsight Abilities
22. Disclaimer
Download Sample PDF Report – https://www.delveinsight.com/sample-request/emphysema-market
About DelveInsight
DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing complete end-to-end solutions to improve their performance.
Other Latest DelveInsight Reports
Acquired Immune Deficiency Syndrome Market
by DelveInsight”Acquired Immune Deficiency Syndrome Market“The report provides an in-depth understanding of historical and forecasted epidemiology, Acquired Immune Deficiency Syndrome market size and stock analysis in the 7MM (i.e. US, L EU5 (Germany, Spain, Italy, France and UK) and Japan) as well as emerging therapies and key companies in the therapeutic area.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Ankit Nigam
E-mail: Send an email
Call: +19193216187
Address:304 S. Jones Boulevard #2432
Town: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/emphysema-market
Comments are closed.